TB-500 Side Effects
TB-500 side effects — the common mild reactions, the rare serious ones, who should avoid it, how to reduce them, and what the thymosin-β4 human data does and doesn't show.
TB-500 (a thymosin-β4 fragment) is reported as generally well tolerated, with side effects usually limited to mild injection-site reactions, occasional fatigue, or a brief head-rush after a loading dose. Its long ~14-day half-life means it accumulates, so over-frequent dosing is the main avoidable problem. As with BPC-157, there are no completed human musculoskeletal trials — the human profile is anecdotal, the reassurance is preclinical, and the angiogenesis/cell-migration mechanism makes active cancer a precautionary contraindication.
The honest starting point on TB-500 side effects: reported reactions are usually mild — injection-site effects, occasional fatigue, a brief head-rush during loading. TB-500’s defining pharmacological feature is its long ~14-day half-life, which means it accumulates, so the most common avoidable issue is dosing too frequently. Like BPC-157, it has no completed human musculoskeletal trial, so the sections below separate commonly-reported effects from rare serious ones, note who should avoid it, and explain how to reduce your risk.
Common side effects
| Effect | Frequency | Notes |
|---|---|---|
| Injection-site reactions (redness, small welt) | Common, mild | Fades within an hour; TB-500 is systemic, so rotate sites for comfort |
| Fatigue / lethargy | Occasional | Most often during loading; ease the dosing interval if it persists |
| Brief head-rush / flushing | Occasional | Shortly after a loading dose |
| Head-cold-like malaise | Uncommon, anecdotal | Reported during initial loading in some users |
Serious & rare effects
- Allergic reaction — Rare — facial/throat swelling, hives, or difficulty breathing require emergency care
- Injection-site infection — Technique-related — spreading redness, heat, pus, or fever
Who should avoid it
- Active or suspected cancer — TB-500 promotes angiogenesis and cell migration; a theoretical concern in malignant/metastatic disease makes it a precautionary contraindication
- Pregnancy and breastfeeding — no safety data
- Children — no safety data
Feeling something? Check here
- Mild, transient injection-site redness or a small welt that fades within an hour
- Brief head-rush or mild fatigue after a loading dose
- Persistent lethargy or headache during loading — extend the interval between doses
- Injection-site lumps or bruising lasting more than a day — rotate sites, check technique
- Facial/throat swelling, difficulty breathing, hives — stop and seek emergency care
- Signs of injection-site infection — spreading redness, heat, pus, fever
- Any new or growing lump elsewhere — growth/repair peptides are contraindicated with active or suspected cancer
Anchored to a phase-1 thymosin β4 trial (54 healthy volunteers, 0.05–25 mcg/kg IV) that reported mild-to-moderate adverse events with no dose-limiting toxicity; no completed musculoskeletal human trial exists for TB-500.
This self-check is educational, not a diagnosis. When in doubt, stop dosing and consult a qualified healthcare provider.
How to reduce side effects
- Respect the long ~14-day half-life: load twice weekly, then drop to weekly maintenance — daily dosing over-accumulates TB-500 with no added benefit
- If loading causes fatigue or malaise, extend the interval between doses rather than pushing through
- Rotate injection sites with sterile technique to avoid site reactions and infection
- Buy only third-party-tested product with a batch-specific Certificate of Analysis — quality is the dominant real-world risk